The goal of this study was to improve the stratification of patients with grade II/III gliomas to prognostic groups by molecular profiling.
Molecular profiling of cerebral gliomas distinguishes biologically distinct tumor groups and provides prognostically relevant information beyond histological classification and IDH1/2 mutation status. We performed microarray-based genome- and transcriptome-wide molecular profiling of primary tumor samples from 137 patients with cerebral gliomas, 61 WHO grade II and 76 WHO grade III tumors.
Matched methylation data is available under LHA-id 7VKP0CRKFE-5
IZBI Härtelstr. 16-18 04107 Leipzig